Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

June 30, 2002

Study Completion Date

May 31, 2007

Conditions
Childhood Malignant Fibrous Histiocytoma of BoneSarcoma
Interventions
DRUG

imatinib mesylate

Trial Locations (10)

10032

Herbert Irving Comprehensive Cancer Center at Columbia University, New York

20010

Washington Hospital Center, Washington D.C.

55905

Mayo Clinic Cancer Center, Rochester

60068

Lutheran General Cancer Care Center, Park Ridge

90095-1781

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

48109-0912

University of Michigan Comprehensive Cancer Center, Ann Arbor

10021-6007

Memorial Sloan-Kettering Cancer Center, New York

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00031915 - Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma | Biotech Hunter | Biotech Hunter